Cite
HARVARD Citation
Borthakur, G. et al. (2021). A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer. 127 (16), pp. 2943-2953. [Online].